BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18628487)

  • 1. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.
    O'Shea D; O'Riain C; Taylor C; Waters R; Carlotti E; Macdougall F; Gribben J; Rosenwald A; Ott G; Rimsza LM; Smeland EB; Johnson N; Campo E; Greiner TC; Chan WC; Gascoyne RD; Wright G; Staudt LM; Lister TA; Fitzgibbon J
    Blood; 2008 Oct; 112(8):3126-9. PubMed ID: 18628487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
    Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
    Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
    Davies AJ; Lee AM; Taylor C; Clear AJ; Goff LK; Iqbal S; Cuthbert-Heavens D; Calaminici M; Norton AJ; Lister TA; Fitzgibbon J
    Leukemia; 2005 Aug; 19(8):1459-65. PubMed ID: 15902285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
    Correia C; Schneider PA; Dai H; Dogan A; Maurer MJ; Church AK; Novak AJ; Feldman AL; Wu X; Ding H; Meng XW; Cerhan JR; Slager SL; Macon WR; Habermann TM; Karp JE; Gore SD; Kay NE; Jelinek DF; Witzig TE; Nowakowski GS; Kaufmann SH
    Blood; 2015 Jan; 125(4):658-67. PubMed ID: 25452615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.
    Bellido M; Capello D; Altés A; Estivill C; Gaidano G; Pujol R; Bordes R; Baiget M; Saglio G; Sierra J; Nomdedéu JF
    Haematologica; 2002 Sep; 87(9):908-17. PubMed ID: 12217802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
    Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
    J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
    Federico M; Bellei M; Marcheselli L; Luminari S; Lopez-Guillermo A; Vitolo U; Pro B; Pileri S; Pulsoni A; Soubeyran P; Cortelazzo S; Martinelli G; Martelli M; Rigacci L; Arcaini L; Di Raimondo F; Merli F; Sabattini E; McLaughlin P; Solal-Céligny P
    J Clin Oncol; 2009 Sep; 27(27):4555-62. PubMed ID: 19652063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma.
    Khanlari M; Wang SA; Fowler NH; Tang G; Saluja K; Muzzafar T; Medeiros LJ; Thakral B
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e626-e629. PubMed ID: 33867306
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.